Evogene Ltd
EVGN
View Detailed Chart
0.782USD
-0.038-4.60%
Market hours （ET）Quotes delayed by 15 min
1.44MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.60%
5 Days
-7.53%
1 Month
-10.88%
6 Months
-33.71%
Year to Date
-28.88%
1 Year
-40.28%
View Detailed Chart
TradingKey Stock Score of Evogene Ltd
Currency: USD Updated: 2026-03-27Key Insights
Evogene Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 109 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.75.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evogene Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Evogene Ltd Highlights
StrengthsRisks
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.85M.
Undervalued
The company’s latest PE is -0.76, at a low 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.82.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
1.750
Target Price
+113.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Evogene Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Evogene Ltd Info
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Ticker SymbolEVGN
CompanyEvogene Ltd
CEOEmber (Brian)
Websitehttps://evogene.com/
Related Instruments
-0.85%
+1.25%
+1.38%
+2.95%
+0.20%
+1.61%
+0.28%
+0.42%
+0.64%
+1.27%
+1.81%
0.00%
+0.78%
+1.94%
-2.95%
0.00%
+0.37%
+2.08%
+2.01%
-1.64%Popular Symbols
246.525
-2.275 (-0.91%)
167.385
-0.135 (-0.08%)
67689.180
+1105.130 (+1.66%)
258.680
-16.660 (-6.05%)
2068.710
+68.710 (+3.44%)
362.800
+0.970 (+0.27%)
4538.270
+45.750 (+1.02%)
101.252
+0.643 (+0.64%)
1.146
-0.005 (-0.40%)
159.535
-0.717 (-0.45%)
